FOXM1 and non-small cell lung carcinoma: The collective findings of this study suggest the potential value of FOXM1 in the inhibition of immune checkpoint molecules alone or in combination with other conventional immune checkpoint inhibitors and may prove to be a better strategy for improving the overall prognosis of patients with NSCLC.